Digital Immunophenotyping of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Subtypes With Specific Tumor-Immune Microenvironment Features
Atypical carcinoids (ACs) and large cell neuroendocrine carcinomas (LCNECs) are defined by the WHO as intermediate- and high-grade lung neuroendocrine neoplasms, respectively, based on morphological criteria; however, treatment strategies remain debated. Given the emerging role of the tumor microenvironment (TME) and tumor-infiltrating lymphocytes (TILs) in cancer prognosis and therapy response, this study aimed to characterize the immune landscape of ACs and LCNECs comprehensively. Immunohistochemistry for T-cell markers (CD3, CD8), immune checkpoints (PD-1, PD-L1), HLA molecules (HLA-DR, HLA-I), and fibroblasts (α-SMA) was performed on a re-evaluated cohort of 56 ACs and 104 LCNECs. Digital image analysis quantified intra-tumor (iTILs) and stromal (sTILs) CD3 and CD8 TILs in the whole slide and in specific tumor regions (invasive margin [IM] and central tumor [CT]). LCNECs exhibited significantly higher stromal T-cell infiltration, immune checkpoint expression, and HLA compared to ACs (p < 0.001), while α-SMA was more prominent in ACs. No ACs showed PD-L1 tumor expression. Digital quantification confirmed greater iTILs and sTILs in LCNECs across all regions, with moderate concordance to manual counts. Interestingly, TIL parameters were higher at the IM than in the CT (p < 0.001). Using Boruta feature selection algorithm, Principal Component Analysis and Hierarchical Clustering, three patient clusters were identified: Cluster 1 (mainly ACs, low TILs, favorable prognosis), Cluster 2 (mixed histology, intermediate TILs, moderate prognosis), and Cluster 3 (mostly LCNECs, high TILs, poor prognosis), with distinct TME marker profiles. PD-L1 tumor expression was strongly linked to Cluster 3. These findings suggest that ACs and LCNECs may be stratified into three distinct immune clusters, highlighting the heterogeneity of their tumor microenvironment and providing a rationale for further translational studies.
Authors
- Alfredo Berruti (ORCID: https://orcid.org/0000-0002-3956-0043)
- Federica Grillo (ORCID: https://orcid.org/0000-0001-6477-3182)
- Stefano Ferrero (ORCID: https://orcid.org/0000-0002-3715-0737)
- Massimo Milione (ORCID: https://orcid.org/0000-0002-1202-139X)
- Patrick Maisonneuve (ORCID: https://orcid.org/0000-0002-5309-4704)
- Alessandro Del Gobbo
- Luigi Rolli (ORCID: https://orcid.org/0000-0002-6673-5785)
- Maria Sole Gallazzi
- Vincenzo Lagano (ORCID: https://orcid.org/0000-0002-5965-0361)
- Ugo Pastorino (ORCID: https://orcid.org/0000-0001-9974-7902)
- Sara Pusceddu (ORCID: https://orcid.org/0000-0002-5096-660X)
- Andrea Tironi
- Giovanna Sabella (ORCID: https://orcid.org/0000-0002-1673-424X)
- Mauro Roberto Benvenuti (ORCID: https://orcid.org/0000-0002-7187-7550)
- Giovanni Centonze (ORCID: https://orcid.org/0000-0003-2864-7941)
- Paola Spaggiari (ORCID: https://orcid.org/0000-0003-2905-1736)
- Luca Roz (ORCID: https://orcid.org/0000-0001-5817-7149)
- Paola Bossi (ORCID: https://orcid.org/0000-0003-2024-6668)
- Émilie Mathian (ORCID: https://orcid.org/0000-0001-7175-4318)
- Luisa Bercich
- Matthieu Foll (ORCID: https://orcid.org/0000-0001-9006-8436)
- Alessandro Mangogna (ORCID: https://orcid.org/0000-0001-7910-1274)
- Carlo Capella
- Rosalia Romano
Institutions
- University of Insubria (IT)
- University of Udine (IT)
- Humanitas University (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Azienda Sanitaria Locale CN2 (IT)
- Ospedale Policlinico San Martino (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Centre international de recherche sur le cancer (FR)
- European Institute of Oncology (IT)
- University of Brescia (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Endocrine Pathology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1007/s12022-025-09886-9
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Ministero della Salute
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione Italiana per la Ricerca sul Cancro